PUBLISHER: DelveInsight | PRODUCT CODE: 1128287
PUBLISHER: DelveInsight | PRODUCT CODE: 1128287
"Sapablursen Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Sapablursen for Polycythemia Vera in the 7MM. A detailed picture of the Sapablursen for Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Sapablursen for Polycythemia Vera. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Sapablursen market forecast, analysis for Polycythemia Vera in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Polycythemia Vera.
Sapablursen, formerly known as IONIS-TMPRSS6-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transmembrane protease, serine 6, or TMPRSS6, to treat anemia and iron toxicity.
TMPRSS6 is a protein produced in the liver that plays an important role in the regulation of the body's iron homeostasis through the control of the iron regulatory protein hepcidin. Inhibition of TMPRSS6 leads to increased hepcidin production, which results in more effective red blood cell production (erythropoiesis) in the bone marrow and reduced iron toxicity in the liver as a result of improved control of iron availability. Sapablursen is now being invested in a Phase II trial for the treatment of phlebotomy-dependent Polycythemia Vera.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Sapablursen Analytical Perspective by DelveInsight
This report provides a detailed market assessment of Sapablursen in Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of Sapablursen for Polycythemia Vera covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions